Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AHMED M MALIK

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1679548135
CMS profile
348646
Location
MILWAUKEE, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,453.91

72 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,375.63 68
Education $78.28 4

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AHMED M MALIK

NPI 1679548135 · CMS profile ID 348646

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

MILWAUKEE, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679548135?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AHMED M MALIK, NPI 1679548135, CMS profile ID 348646. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679548135?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). AHMED M MALIK, NPI 1679548135, CMS profile ID 348646. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679548135?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
AHMED M MALIK, NPI 1679548135, CMS profile ID 348646, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1679548135?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

72 matching records · $1,453.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 72 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–72 of 72.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $5.7804/28/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915469395 CMS
GlaxoSmithKline, LLC. $21.2404/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944625155 CMS
Aurinia Pharma U.S., Inc. $19.0504/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954091695 CMS
Vifor Pharma, Inc. $16.9804/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896760339 CMS
Vifor Pharma, Inc. $16.9804/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896760341 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.0703/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929933575 CMS
Mallinckrodt Hospital Products Inc. $16.9703/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937510699 CMS
Ultragenyx Pharmaceutical Inc. $16.2603/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963735383 CMS
Bard Peripheral Vascular, Inc. $57.5303/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936014929 CMS
Fresenius USA Marketing, Inc. $17.4303/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954554019 CMS
Exeltis, USA Inc. $27.7203/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947105109 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.5503/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887393051 CMS
AstraZeneca Pharmaceuticals LP $22.3702/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914760149 CMS
AstraZeneca Pharmaceuticals LP $16.4102/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915640001 CMS
Vifor Pharma, Inc. $18.6702/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896760349 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.6102/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955714707 CMS
Otsuka America Pharmaceutical, Inc. $19.1602/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929309081 CMS
GlaxoSmithKline, LLC. $16.1801/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944625151 CMS
Horizon Therapeutics plc $24.8601/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937656081 CMS
Ultragenyx Pharmaceutical Inc. $13.2001/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963732147 CMS
AMAG Pharmaceuticals, Inc. $17.1001/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953401525 CMS
Amgen Inc. $12.0401/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933773613 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,694.46 108
PY2020 $4,345.61 52
PY2021 $1,231.31 67
PY2022 $1,453.91 72
PY2023 $1,766.37 85
PY2024 $1,989.81 90
PY2025 $2,142.25 96

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2019 Principal investigator $7,539.62 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AKEBIA THERAPEUTICS INC $593.06 12/11/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152117
Principal investigator 1 AKEBIA THERAPEUTICS INC $207.80 12/11/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152119
Principal investigator 1 AKEBIA THERAPEUTICS INC $25.00 12/11/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152121
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 12/11/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152123
Principal investigator 1 AKEBIA THERAPEUTICS INC $90.00 12/11/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152125
Principal investigator 1 AKEBIA THERAPEUTICS INC $80.00 12/11/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152127
Principal investigator 1 AKEBIA THERAPEUTICS INC $136.86 11/05/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152111
Principal investigator 1 AKEBIA THERAPEUTICS INC $124.68 11/05/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152113
Principal investigator 1 AKEBIA THERAPEUTICS INC $8.16 11/05/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152115
Principal investigator 1 AKEBIA THERAPEUTICS INC $100.00 10/29/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152107
Principal investigator 1 AKEBIA THERAPEUTICS INC $60.00 10/29/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152109
Principal investigator 1 AKEBIA THERAPEUTICS INC $200.00 09/10/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152105
Principal investigator 1 AKEBIA THERAPEUTICS INC $94.00 07/17/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152101
Principal investigator 1 AKEBIA THERAPEUTICS INC $64.99 07/17/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152103
Principal investigator 1 AKEBIA THERAPEUTICS INC $18.42 06/26/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152099
Principal investigator 1 AKEBIA THERAPEUTICS INC $6.06 06/07/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152095
Principal investigator 1 AKEBIA THERAPEUTICS INC $64.99 06/07/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152097
Principal investigator 1 AKEBIA THERAPEUTICS INC $16.25 05/31/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152093
Principal investigator 1 AKEBIA THERAPEUTICS INC $10.00 05/22/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152079
Principal investigator 1 AKEBIA THERAPEUTICS INC $393.64 05/22/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152081
Principal investigator 1 AKEBIA THERAPEUTICS INC $22.75 05/22/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152083
Principal investigator 1 AKEBIA THERAPEUTICS INC $50.00 05/22/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152085
Principal investigator 1 AKEBIA THERAPEUTICS INC $100.00 05/22/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152087
Principal investigator 1 AKEBIA THERAPEUTICS INC $150.00 05/22/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152089
Principal investigator 1 AKEBIA THERAPEUTICS INC $90.00 05/22/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152091
Principal investigator 1 AKEBIA THERAPEUTICS INC $150.00 04/30/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152075
Principal investigator 1 AKEBIA THERAPEUTICS INC $200.00 04/30/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152077
Principal investigator 1 AKEBIA THERAPEUTICS INC $20.00 04/19/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152071
Principal investigator 1 AKEBIA THERAPEUTICS INC $393.64 04/19/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152073
Principal investigator 1 AKEBIA THERAPEUTICS INC $50.00 04/02/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152069
Principal investigator 1 AKEBIA THERAPEUTICS INC $17.25 03/25/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152061
Principal investigator 1 AKEBIA THERAPEUTICS INC $5.85 03/25/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152063
Principal investigator 1 AKEBIA THERAPEUTICS INC $88.81 03/25/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152065
Principal investigator 1 AKEBIA THERAPEUTICS INC $58.00 03/25/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152067
Principal investigator 1 AKEBIA THERAPEUTICS INC $521.50 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152023
Principal investigator 1 AKEBIA THERAPEUTICS INC $240.00 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152025
Principal investigator 1 AKEBIA THERAPEUTICS INC $10.90 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152027
Principal investigator 1 AKEBIA THERAPEUTICS INC $150.00 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152029
Principal investigator 1 AKEBIA THERAPEUTICS INC $200.00 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152031
Principal investigator 1 AKEBIA THERAPEUTICS INC $90.00 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152033
Principal investigator 1 AKEBIA THERAPEUTICS INC $480.00 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152035
Principal investigator 1 AKEBIA THERAPEUTICS INC $240.00 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152037
Principal investigator 1 AKEBIA THERAPEUTICS INC $927.04 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152039
Principal investigator 1 AKEBIA THERAPEUTICS INC $11.42 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152041
Principal investigator 1 AKEBIA THERAPEUTICS INC $442.29 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152043
Principal investigator 1 AKEBIA THERAPEUTICS INC $90.00 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152045
Principal investigator 1 AKEBIA THERAPEUTICS INC $43.50 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152047
Principal investigator 1 AKEBIA THERAPEUTICS INC $17.25 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152049
Principal investigator 1 AKEBIA THERAPEUTICS INC $17.55 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152051
Principal investigator 1 AKEBIA THERAPEUTICS INC $16.83 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152053
Principal investigator 1 AKEBIA THERAPEUTICS INC $10.65 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152055
Principal investigator 1 AKEBIA THERAPEUTICS INC $299.48 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152057
Principal investigator 1 AKEBIA THERAPEUTICS INC $11.00 01/18/2019 Non-covered Recipient Entity
MILWAUKEE NEPHROLOGISTS, SC
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) No dispute reported 06/30/2026 707152059